

TAKHZYRO® (lanadelumab) Prescribing Information can be found [here](#).  
 CINRYZE™ (human C1-esterase inhibitor) Prescribing Information can be found [here](#).

Adverse events should be reported. Reporting forms and information can be found at: <https://yellowcard.mhra.gov.uk/>  
 Adverse events should also be reported to Takeda at: [AE.GBR-IRL@takeda.com](mailto:AE.GBR-IRL@takeda.com)


## A TAKEDA SUMMARY

# Prophylaxis in hereditary angioedema a United Kingdom Delphi consensus<sup>1</sup>


Since the last UK consensus statement in 2014, new effective licensed therapies for LTP in HAE have been approved for use by NICE in the UK, including TAKHZYRO and berotralstat. Additionally, NHS England published a policy for commissioning of plasma-derived C1 inhibitor for LTP in 2016, in which access criteria have been restricted primarily by HAE attack frequency.<sup>1</sup>

In view of the changes to the HAE landscape, a further Delphi consensus was conducted in 2021 with the aim of establishing current views on the management of LTP for HAE in the UK to highlight potential areas of improvement.<sup>1</sup>

The 2021 WAO/EAACI HAE guidelines currently recommend the use of LTP as the only way of achieving total disease control and to normalise patients' lives.<sup>2</sup>



## The Delphi method<sup>1</sup>



### Exploration phase

Telephone interviews with experts to identify broad issues

Responses edited and used to construct questionnaires  
**41 consensus statements were finalised**



### Evaluation phase

Conducted 25 June–25 July 2021  
 Specific questionnaires involving:

**59** HCPs    **39** patients    **34** centres

The level of individual agreement with each statement was measured using a four-point Likert scale (strongly disagree, disagree, agree, or strongly agree)

## Key areas for action identified by HCPs (% agreement with statement)<sup>1</sup>

### Prophylaxis

Agreement was **100%** for all statements within this theme, related to:

- Desired outcomes for LTP**  
To significantly reduce attack frequency and severity, and improve patient QoL
- Tolerability**  
LTP should be well tolerated
- Ease of use**  
LTP should be easy to self-administer, and not unduly burdensome
- Provision of information to patients**  
Including efficacy, safety, and route of administration, to enable an informed choice
- The benefits of well-controlled disease**  
Improves patient QoL and utilises fewer healthcare resources

### Commissioning of prophylaxis for HAE

is based on too simplistic criteria – attack frequency alone is not appropriate...

...potentially limiting the access of a cohort of patients who should be given prophylaxis

**83.9%** agree

**78.6%** agree

### Alternatives to the current CCP are preferable.

They could include a form of validated PRO scoring in conjunction with a peer-review process

**96.4%** agree


### The prophylaxis policy should also take into account:

- Attack severity
- Duration of attack
- Attack location
- Impact of HAE on the patient

**96.4%** agree

**80.4%** agree

Compared with other countries,\* the prophylaxis policy is far more stringent and restrictive, putting patients in the UK at a comparative disadvantage




### Attenuated androgens

are effective for some patients, but unsuitable for specific groups (e.g. children and pregnant women)

**100%** agree


The WAO/EAACI HAE guidelines only recommend androgens as second line therapy.<sup>2</sup> Additionally, given the known side effects of danazol and the potential association of HAE with cardiovascular disease,<sup>3</sup> this highlights a case for review of the current access policies in the UK

### Standardisation of patient reviews could improve:



Objective assessment and access to treatment

**91.2%** agree



Comparison of HAE management across the UK

**96.5%** agree

Data collection

**98.2%** agree



### Patient management

should involve regular reviews and evaluations for LTP at every visit (at least once per year), in line with national and international guidelines

**94.7%** agree

### The disease burden of HAE

is very individual; what may appear to not be a high disease burden can have a huge impact on a patient, and vice versa

**98.2%** agree

Psychological support is recognised as an area of potential benefit requiring further resources and research

### Remote patient management

remains popular post-pandemic, particularly for stable patients...

**94.7%** agree

...and is something that has been identified as having benefits



### Expert patient care


in specialist centres should be provided for patients with HAE

These centres should maintain a sufficient cohort of patients to ensure expertise, or work within a coordinated network of HAE specialists



**98.3%** agree

**96.6%** agree



### PRO measures

are valuable tools that could enable patient benchmarking and disease tracking over time and facilitate reviews

### Limitations of the survey included:

- Not all HAE consultants may have been included
- Potential bias in patient recruitment
- The need to explore views on on-demand treatment for HAE in future research

Use this document with commissioners or service leads to advocate for improvements to standards of care in HAE.

TAKHZYRO is indicated for routine prevention of recurrent attacks of HAE in patients aged 2 years and older.<sup>4,5</sup>

CINRYZE is indicated for the treatment and pre-procedure prevention of angioedema attacks in adults, adolescents and children (2-years old and above) with HAE; routine prevention of angioedema attacks in adults, adolescents and children (6-years old and above) with severe and recurrent attacks of HAE, who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.<sup>6,7</sup>

This project was funded by an independent health care consultancy, the MASS Team, initiated and funded by Takeda UK.

This summary is written and based by Takeda, but Takeda had no involvement in the interpretation and the writing of the full publication.

\*No attack metric connected to access of TAKHZYRO in Germany, France and Spain.

**Abbreviations:** CCP, clinical commissioning policy; HAE, hereditary angioedema; HCP, healthcare professional; LTP, long-term prophylaxis; NICE, National Institute for Health and Care Excellence; PRO, patient-reported outcome; QoL, quality of life; WAO/EAACI, World Allergy Organization/European Academy of Allergy and Clinical Immunology.

**References:** 1. Yong PFK, et al. *Clin Exp Immunol* 2024;217(1):100–116; 2. Maurer M, et al. *Allergy*. 2022;77(7):1961–1990; 3. Sundler Björkman L, et al. *Clin Transl Allergy*. 2022;12(3):e12135; 4. TAKHZYRO GB Summary of Product Characteristics; 5. TAKHZYRO NI Summary of Product Characteristics; 6. CINRYZE GB Summary of Product Characteristics; 7. CINRYZE NI Summary of Product Characteristics.

©2024 Takeda UK Limited. All rights reserved. The Takeda Logo® is a registered trademark of Takeda Pharmaceutical Company Limited. TAKHZYRO is a registered trademark of Dyax Corp. CINRYZE and the CINRYZE logo are registered trademarks of ViroPharma Biologics LLC.

Takeda UK Limited, 1 Kingdom Street, London, W2 68D, United Kingdom.

